 Home > Active Ingredient News > Antitumor Therapy > Transl Oncol: Metformin-salicylic acid treatment can improve prostate cancer treatment

Transl Oncol: Metformin-salicylic acid treatment can improve prostate cancer treatment

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

aspirin anti inflammatory dose

anti citrulline antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Prostate cancer (PrCa) is the most common male cancer in Western countries
.

Radiotherapy (RT) is the main treatment for all stages of prostate cancer, but prostate tumors are resistant to this treatment

Anti- diabetic drugs metformin (MET) and aspirin metabolite salicylate (SAL) can activate AMP protein kinase (AMPK) and inhibit adipogenesis (DNL) and mammalian rapamycin (mTOR) pathways, and can reduce in vitro Proliferation of PrCa
.

Diabetic metformin

Recently, researchers from Canada published an article in "Transl Oncol", investigating whether MET+SAL treatment can enhance PrCa tumor suppression and improve the response to RT
.

Investigated whether MET+SAL treatment can enhance the PrCa tumor suppression effect and improve the response to RT.
Investigate whether MET+SAL treatment can enhance the PrCa tumor suppression effect and improve the response to RT.

The researchers used androgen-sensitive (22RV1) and resistant (PC3, DU-145) PrCa cells and PC3 xenografts to investigate whether MET+SAL treatment is better than MET or SAL alone in inhibiting PrCa cells and Tumor activity
.

The mechanism of action was investigated by analyzing signal pathways, mitochondrial respiration and DNL activity determination

It was found that PrCa cells are resistant to clinical doses of MET
.

MET+SAL treatment can produce synergistic anti-proliferative activity at clinical doses and enhance the anti-proliferative effect of RT

Metformin + salicylic acid can inhibit tumor growth and DNA replication

In summary, MET+SAL treatment can inhibit the proliferation of PrCa cells and tumor growth, and enhance the response to RT at clinical doses
.

MET and SAL are widely used safely and cheaply.

MET+SAL treatment can inhibit the proliferation of PrCa cells and tumor growth, and enhance the response to RT at clinical doses MET+SAL treatment can inhibit the proliferation of PrCa cells and tumor growth, and enhance the response to RT at clinical doses

Original source:

Evangelia E Tsakiridis, Lindsay Broadfield, Katarina Marcinko et al.

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.